Eisai to Launch Leqembi (Lecanemab) in Japan for the Treatment of Alzheimer’s Disease (AD)
Shots:
- Eisai expect to launch Leqembi (lecanemab) in Japan on Dec 20, following its inclusion in the Japan NHI Drug Price List. The drug has received approval in Japan for both manufacturing & marketing for slowing the progression of MCI & mild dementia due to AD
- The approval was based on the P-III study which met its 1EP that involves the CDR-SB reduction at 18mos. by 27% vs PBO & 2EP includes ADCS MCI-ADL that demonstrated a statistically significant benefit of 37% vs PBO
- Leqembi, humanized mAb already approved in the US for AD is set to be co-promoted in Japan by Eisai & Biogen. Eisai has also submitted applications for approval in 12 countries & regions, incl. the EU & China, with priority review designations in China & Israel
Ref: EISAI | Image: EISAI
Related News:- Eisai and BioArctic Presented Results of Leqembi as Subcutaneous Dosage Form in P-III Trial for Alzheimer’s Disease CTAD 2023
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
